newsfilter
← Latest News
GlobeNewswire·

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third